Ocular Therapeutix

Performance

About Ocular Therapeutix

Ocular Therapeutix is a biopharmaceutical company focused on developing ophthalmic therapies for retinal diseases. The company is advancing AXPAXLI, a sustained-release axitinib hydrogel delivered via intravitreal injection to treat conditions like wet age-related macular degeneration. Their work aims to reduce treatment burden and improve long-term retinal outcomes, with operations centered on retinal disease management and innovation in the United States. They emphasize innovative drug delivery technologies to redefine retina care.